Oncimmune announces a the raise of a minimum of £2.0 million equity and an amendment to the facility agreement with IPF Partners, including a partial conversion of debt to equity
Oncimmune Holdings plc, the leading global immunodiagnostics group, today announces that it has sold its wholly-owned subsidiaries, Oncimmune Limited (including the CEmarked IVD EarlyCDT® Lung blood test, antibody platform and research and development pipeline) and Oncimmune Europe GmbH to Freenome Holdings, Inc. for a total of £13M in cash.
Oncimmune will continue to operate its ImmunoINSIGHTS business, primarily through its subsidiary Oncimmune Germany GmbH.